Prevalence of haemochromatosis gene mutations in Parkinson’s disease

The aim of this study was to investigate a possible association between haemochromatosis (HFE) gene mutations and the prevalence of Parkinson’s disease. The HFE gene encodes a protein that modulates iron absorption. Several studies have documented increased iron levels in the basal ganglia in patients with Parkinson’s disease. In a study on patients with concurrent hereditary haemochromatosis and Parkinson’s disease, abnormal deposition of iron in the basal ganglia was suggested as an inductor of Parkinson’s disease. In this study, genotype frequencies of the HFE mutations C282Y, H63D and S65C were estimated in 388 patients with Parkinson’s disease and compared with frequencies found in comparable studies. No significant differences were found in frequencies between the patients and comparable populations. This study does not indicate increased susceptibility to Parkinson’s disease in HFE gene mutation carriers in Norway.

[1]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  K. Hirji.  Exact Analysis of Discrete Data , 2005 .

[3]  Mathias Toft,et al.  Clinical features of LRRK2‐associated Parkinson's disease in central Norway , 2005, Annals of neurology.

[4]  Joseph Jankovic,et al.  Neurodegenerative disease and iron storage in the brain , 2004, Current opinion in neurology.

[5]  D. Costello,et al.  Concurrent hereditary haemochromatosis and idiopathic Parkinson’s disease: a case report series , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[6]  Xudong Huang,et al.  Iron inhibits neurotoxicity induced by trace copper and biological reductants , 2004, JBIC Journal of Biological Inorganic Chemistry.

[7]  A. Hofman,et al.  Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism , 2003, Neuroscience Letters.

[8]  E. Hirsch,et al.  Neuromelanin associated redox‐active iron is increased in the substantia nigra of patients with Parkinson's disease , 2003, Journal of neurochemistry.

[9]  P. Silburn,et al.  The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients , 2002, Neuroscience Letters.

[10]  Y. Agid,et al.  Association study between iron-related genes polymorphisms and Parkinson's disease , 2002, Journal of Neurology.

[11]  K. Hveem,et al.  Screening for Hemochromatosis: High Prevalence and Low Morbidity in an Unselected Population of 65,238 Persons , 2001, Scandinavian journal of gastroenterology.

[12]  E. Broussolle,et al.  Clinical report of three patients with hereditary hemochromatosis and movement disorders , 2000, Movement disorders : official journal of the Movement Disorder Society.

[13]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[14]  O. Rascol,et al.  Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study , 1998, Movement disorders : official journal of the Movement Disorder Society.

[15]  Wiklund Ra,et al.  First of two parts , 1997 .

[16]  M. C. Ellis,et al.  A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis , 1996, Nature Genetics.

[17]  C. Férec,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS HFE Mutations Analysis in 711 Hemochromatosis Probands: Evidence for S65C Implication in Mild Form of Hemochromatosis , 2016 .

[18]  D. Berg,et al.  The basal ganglia in haemochromatosis , 2000, Neuroradiology.

[19]  J. Berg,et al.  High prevalence of the hemochromatosis-associated Cys282Tyr HFE gene mutation in a healthy Norwegian population in the city of Oslo, and its phenotypic expression. , 1999, Scandinavian journal of gastroenterology.

[20]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[21]  E. Hirsch,et al.  Iron metabolism and Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.